Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2023
Immune checkpoint inhibitors continue to dominate the treatment of non-small cell lung cancer (NSCLC), and biomarker-based approaches are increasingly segmenting the space and providing new treatment options. In December 2022, Krazati became the second KRAS inhibitor to enter the U.S. market (after Lumakras). Enhertu, the first targeted therapy for previously treated HER2-mutant metastatic NSCLC, was approved in August 2022. In addition, in November 2022, the FDA approved the CTLA4 inhibitor Imjudo for use with Imfinzi and chemotherapy for certain metastatic NSCLC patients. These new entrants, against a backdrop of chemotherapies, immune checkpoint inhibitors, and existing biomarker-driven agents, provide medical oncologists with an ever-increasing array of treatment options.
Questions answered
- What are the treatment rates for metastatic NSCLC in the various lines of therapy?
- What are the rates of testing for different biomarkers, and what is the uptake of key biomarker-driven therapies?
- How are new therapy entrants to the metastatic NSCLC market performing relative to existing therapies?
- What do surveyed physicians consider the main drivers of and key obstacles to the uptake of select therapies?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 100 U.S. medical oncologists.
Key drugs covered:
Alecensa, Enhertu, Exkivity, Gavreto, Imfinzi, Imjudo, Keytruda, Krazati, Libtayo, Lumakras, Opdivo, Retevmo, Rybrevant, Tabrecta, Tagrisso, Tecentriq, Tepmetko, Yervoy
